Physician profile
Clifford E Sloop
NPI 1548630452
$7,310.11
in general payments reported to CMS, 2019-2025
38 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $729 · 2022: $1,502 · 2023: $1,656 · 2024: $1,801 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,041 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,041.05 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.52 | 2021-2025 | |
| Lilly USA, LLC | $768.11 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $537.67 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $512.02 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $424.61 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $423.73 | 2023-2025 | |
| Amgen INC. | $351.29 | 2022-2025 | Repatha, Repatha, Evenity |
| Novo Nordisk INC | $292.39 | 2022-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $277.51 | 2021-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.37 | 2022-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $224.94 | 2022-2025 | Spravato, Xarelto |
| Corium, LLC | $212.78 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $172.59 | 2023-2025 | Rexulti |
| Abbott Laboratories | $170.68 | 2022-2023 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.49 | 2021-2025 | Jardiance, Tradjenta |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Sloop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.